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Background: Evidence from in vitro and animal studies indicates that conjugated linoleic acid (CLA) possesses
anti-diabetic properties, which appear to be attributed to cis-9, trans-11 CLA, the major CLA isomer in ruminant fat.
However, there is a shortage of studies addressing CLA from natural source. The present study aimed to evaluate
the effects of butter naturally enriched in cis-9, trans-11 CLA on parameters related to glucose tolerance, insulin
sensitivity and dyslipidemia in rats.
Methods: Forty male Wistar rats were randomly assigned to the following dietary treatments (n = 10/group), for
60 days: 1) Normal fat-Soybean oil (NF-So): diet containing 4.0% soybean oil (SO); 2) High Fat-Control Butter (HF-Cb):
diet containing 21.7% control butter and 2.3% SO; 3) High Fat-CLA enriched Butter (HF-CLAb): diet containing
21.7% cis-9, trans-11 CLA-enriched butter and 2.3% SO; and 4) High fat-Soybean oil (HF-So): diet containing 24.0%
SO. HF-Cb and HF-CLAb diets contained 0.075% and 0.235% of cis-9, trans-11 CLA, respectively.
Results: HF-CLAb-fed rats had lower serum insulin levels at fasting than those fed with the HF-Cb diet, while the
PPARγ protein levels in adipose tissue was increased in HF-CLAb-fed rats compared to HF-Cb-fed rats. Furthermore,
R-QUICK was lower in HF-Cb than in NF-So group, while no differences in R-QUICK were observed among NF-So,
HF-CLAb and HF-So groups. Serum HDL cholesterol levels were higher in HF-CLAb-fed rats than in those fed NF-So,
HF-Cb and HF-So diets, as well as higher in NF-So-fed rats than in HF-Cb and HF-So-fed rats. HF-CLAb, HF-Cb and
HF-So diets reduced serum LDL cholesterol levels when compared to NF-So, whereas serum triacylglycerol levels
were increased in HF-CLAb.
Conclusion: Feeding rats on a high-fat diet containing butter naturally enriched in cis-9, trans-11 CLA prevented
hyperinsulinemia and increased HDL cholesterol, which could be associated with higher levels of cis-9, trans-11 CLA,
vaccenic acid, oleic acid and lower levels of short and medium-chain saturated fatty acids from butter naturally
modified compared to control butter. On the other hand CLA-enriched butter also increased serum triacylglycerol
levels, which could be associated with concomitant increases in the content of trans-9 and trans-10 C18:1 isomers
in the CLA-enriched butter.
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Diabetes mellitus is an important cause of mortality and
morbidity worldwide, with harmful effects on life expect-
ancy and health-care costs [1]. According to the World
Health Organization [2], type 2 diabetes comprises 90%
of the total population with diabetes mellitus around the
world, and is characterized by the body’s ineffective use
of insulin. It is projected that the number of people with
diabetes mellitus worldwide will rise to 439 million by
2030 [3]. There is compelling evidence that diet plays an
important role in the prevention of a number of non-
communicable diseases, including type-2 diabetes [4]. In
this context, conjugated linoleic acid (CLA) has attracted
considerable attention in the scientific community due
to its health-promoting properties reported in a number
of in vitro and animal studies [5]. CLA refers to the pos-
itional and geometric conjugated dienoic isomers of
linoleic acid (C18:2 n-6) [6] which are predominantly
found in ruminant fat [7]. Although nearly twenty
isomers have been identified in ruminant products [8],
75-90% of total CLA is represented by cis-9, trans-11
CLA (rumenic acid) [9], whereas the trans-10, cis-12
CLA isomer is normally found in very low concentra-
tions [10].There is some evidence that the anti-
diabetogenic effects reported in several studies are
mediated by rumenic acid [11], the major CLA isomer
in ruminant fat.
As dairy products are the major source of CLA in the
human diet [7], efforts have been made to increase the
milk fat CLA content, which can be achieved by including
plant oils in the diet of dairy cows [12,13]. Most of the
cis-9, trans-11 CLA secreted in milk is synthesized en-
dogenously from trans-11 C18:1 (vaccenic acid) through
stearoyl-CoA desaturase enzyme (also known as Δ-9
desaturase). Therefore, milk naturally enriched in cis-
9, trans-11 CLA is also a rich source of vaccenic acid
[14]. Endogenous synthesis of cis-9, trans-11 CLA
from C18:1 trans-11 has also been reported in humans
[15] and other species [16,17], which further contrib-
utes to increasing the cis-9, trans-11 CLA levels in the
body tissues. It should also be noted that the concen-
trations of some minor (e.g. trans-C18:1 isomers other
than vaccenic) and major (e.g. medium-chain satu-
rated) fatty acids are also altered in milk fat from cows
fed diets supplemented with plant oils [13], which
should be taken into account when food sources nat-
urally enriched in CLA are used in a given study.
In light of the potential anti-diabetogenic effects of
cis-9, trans-11 CLA observed in previous studies and
the shortage of studies addressing CLA from natural
source, we investigated the effects of a diet containing
butter naturally enriched in cis-9 trans-11 CLA on
glucose tolerance, insulin sensitivity and dyslipidemia
in Wistar rats.Results
Food intake of HF-Cb, HF-CLAb and HF-So diets was
20.76%, 19.54% and 27.60% lower than NF-So food
intake, respectively, while no difference was observed
between HF-Cb, HF-CLAb and HF-So (Table 1). The
energy intake observed in rats fed with the HF-Cb, HF-
CLAb and HF-So diets was 15.85%, 13.95% and 11.04%
higher than in NF-So-fed rats, respectively, but there
was no difference among HF-Cb, HF-CLAb and HF-So
(Table 1). No differences in weight gain (expressed as a
percentage of initial weight) were observed among treat-
ment groups (Table 1).
The effect of NF-So, HF-Cb, HF-CLAb and HF-So di-
ets on body weight during all experimental period is
shown in Figure 1. There were no differences among
dietary treatments.
Concerning the carcass chemical composition, no dif-
ferences in moisture, lipid, protein and ash contents was
observed among groups (Table 1). PPARγ protein levels
in adipose tissue were decreased by 58.70%, 62.35% and
41% in HF-Cb-fed rats in comparison to those fed with
the NF-So, HF-CLAb and HF-So diets, respectively
(Figure 2) (Additional files 1, 2, 3 and 4).
Fasting serum insulin levels increased by 21.73%,
11.60% and 23.65% in HF-Cb-fed rats in comparison
to those fed with the NF-So, HF-CLAb and HF-So
diets, respectively (Figure 3A), whereas there were no
differences in glycemia levels among experimental
groups (Figure 3B). NEFA and leptin did not differ
among dietary treatments (Table 1).
HOMA index was unchanged by the dietary treat-
ments (Table 1). However, the HF-Cb group had a lower
R-QUICKI index (13.63%) than NF-So, while no differ-
ence was observed among HF-CLAb, HF-So and NF-So
groups (Table 1). There were no differences in the area
under the OGTT glycemic curve (AUC) among dietary
treatments (Table 1). Serum cholesterol levels did not
differ between HF-CLAb and NF-So groups, whereas
there were no differences between HF-Cb and HF-So
(Figure 4A). Serum triacylglycerol levels in HF-CLAb
were increased by 58.81%, 49.54% and 131.12% when
compared to NF-So, HF-Cb and HF-So groups, respect-
ively (Figure 4B). Serum levels of HDL cholesterol were
increased by 10.08%, 23.29% and 25.76% in HF-CLAb-
fed rats as compared to those fed with the NF-So, HF-
Cb and HF-So diets, respectively (Figure 4C). There was
no difference in serum LDL cholesterol levels between
rats fed with the HF-Cb and HF-CLAb diets, but values
observed in these groups were 39.68% and 36.88% lower
than in NF-So group, respectively, and 21.05% and
17.37% lower than in HF-So, respectively (Figure 4D).
There was no difference in the LDL cholesterol:HDL
cholesterol ratio between HF-Cb and HF-CLAb groups,
and these values were lower than HF-So result. The LDL
Table 1 Metabolic and serum parameters in Wistar rats fed with control or naturally enriched in cis-9, trans-11 CLA
butters for 60 days
Dietary treatments
NF-So1 HF-Cb2 HF-CLAb3 HF-So4
Dietary intake and weight gain
Intake (g/day/rat) 26.45 ± 1.06 20.96 ± 0.37*** 21.33 ± 0.49*** 19.15 ± 0.49***
Intake (Kcal/day/rat) 63.19 ± 2.52 73.21 ± 1.31** 72.01 ± 1.67** 70.17 ± 1.89*
Weight gain (%) 62.15 ± 1.90 69.31 ± 2.13 66.05 ± 2.41 59.80 ± 3.32
Body composition
Moisture (%) 50.10 ± 1.05 50.03 ± 0.47 48.19 ± 0.44 50.83 ± 1.17
Lipid (%) 29.41 ± 1.38 28.55 ± 0.64 31.31 ± 0.50 27.14 ± 1.36
Protein (%) 17.76 ± 0.32 17.60 ± 0.21 16.96 ± 0.19 17.57 ± 0.49
Ash (%) 3.38 ± 0.05 4.13 ± 0.09 3.66 ± 0.28 3.87 ± 0.38
Insulin Sensibility Indexes and AUC
HOMA index 1.11 ± 0.02 1.40 ± 0.10 1.39 ± 0.16 1.08 ± 0.05
R-QUICKI 0.88 ± 0.02 0.76 ± 0.03* 0.82 ± 0.02 0.81 ± 0.04
AUC 13180 ± 1505 12330 ± 1158 14390 ± 1398 14610 ± 1021
Serum metabolites
NEFA (mmol/L) 0.375 ± 0.023 0.325 ± 0.017 0.354 ± 0.022 0.294 ± 0.025
Leptin (ng/mL) 2.21 ± 0.21 2.59 ± 0.26 2.72 ± 0.35 1.99 ± 0.20
LDL-C5/HDL-C6 1.42 ± 0.07 0.93 ± 0.04***,## 0.81 ± 0.05***,### 1.17 ± 0.06**
non-HDL-C/HDL-C 1.73 ± 0.11 1.39 ± 0.08* 1.33 ± 0.07** 1.46 ± 0.05*
Data are presented as mean values ± S.E.M (n = 10 rats/group). Statistically significant differences were determined by Anova followed by Newman-Keuls. Asterisk
denotes statistically significant differences compared to NF-So (*p < 0.05, **p < 0.01, ***p < 0.001) and number sign denotes statistically significant differences
compared to HF-So (##p < 0.01, ###p < 0.001). 1Normal Fat-Soybean oil (NF-So), diet containing 4.0% soybean oil (SO); 2High Fat-Control Butter (HF-Cb), diet containing
21.7% control butter and 2.3% SO; 3High CLA Butter (HF-CLAb), diet containing 21.7% butter naturally enriched in cis-9, trans-11 CLA and 2.3% SO; 4High Fat-Soybean oil
(HF-So), diet containing 24.0% SO.
5LDL-C: LDL cholesterol; 6HDL-C:HDL cholesterol.
Figure 1 Effect of control or naturally enriched in cis-9, trans-11
CLA butters on body weight. Male Wistar rats fed the following
dietary treatments for 60 days: Normal fat-Soybean oil (NF-So): diet
containing 4.0% soybean oil (SO); High Fat-Control Butter (HF-Cb):
diet containing 21.7% control butter and 2.3% SO; High Fat-CLA
enriched Butter (HF-CLAb): diet containing 21.7% cis-9, trans-11
CLA-enriched butter and 2.3% SO; High fat-Soybean oil (HF-So): diet
containing 24.0% SO. All data are presented as mean values ± S.E.M
(n = 10 rats/group). Statistically significant differences were determined
by Anova followed by Newman-Keuls. *p < 0.05, **p <0.01.
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groups were lower than the value of NF-So (Table 1).
There was no difference in the non-HDL cholesterol:
HDL cholesterol ratio among HF-Cb, HF-CLAb and
HF-So groups, while these values were lower than NF-
So result (Table 1).
Discussion
In recent years, conjugated linoleic acid has received
much attention as a dietary supplement [11], however
few studies assess the effects of CLA from natural
sources on insulin, glucose and serum lipid metabolism.
In this paper, we have demonstrated dietary effects
of cis-9, trans-11 CLA-enriched butter in 60-day-old
Wistar rats on feed intake, body composition, insulin
and glucose metabolism as well as dyslipidemia.
In this study, there were no differences in dietary in-
take among rats fed with cis-9, trans-11 CLA-enriched
butter, control butter or high fat-soybean oil. HF-Cb,
HF-CLAb or HF-So-fed rats adapted to the higher en-
ergy density of these diets by reducing their daily food
intake compared to the NF-So group, as was previously
reported [18]. Daily energy intake was higher in HF-Cb,
Figure 2 Analysis of PPARγ protein level in retroperitoneal adipose tissue. PPARγ levels (A) and representative blot for PPARγ and β-tubulin
(loading control) (additional Electrophoretic blot files show this in more detail [see Additional files 1, 2, 3 and 4]) (B) of male Wistar rats fed the
following dietary treatments for 60 days: Normal fat-Soybean oil (NF-So): diet containing 4.0% soybean oil (SO); High Fat-Control Butter (HF-Cb):
diet containing 21.7% control butter and 2.3% SO; High Fat-CLA enriched Butter (HF-CLAb): diet containing 21.7% cis-9, trans-11 CLA-enriched
butter and 2.3% SO; High fat-Soybean oil (HF-So): diet containing 24.0% SO. All data are presented as mean values ± S.E.M (n = 10 rats/group).
Statistically significant differences were determined by Anova followed by Newman-Keuls. *p <0.05, **p <0.01.
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which can be attributed to the increased palatability of
high fat diets, which is directly related to higher ener-
getic intake [19]. High fat diets are more palatable be-
cause fat content is one of the factors that contribute to
food palatability [19].
Experiments have shown that PPARγ is the master
adipogenic regulator [20] and, interconnected to its role
in adipocyte differentiation, PPARγ regulates insulin sen-
sitivity by transcriptionally activating genes involved in
insulin signaling, glucose uptake, and fatty acid uptake
and storage [21]. HF-CLAb-fed rats presented increased
levels of PPARγ in adipose tissue compared to HF-Cb-
fed rats, which may be attributed to higher (213.20%)
supply of cis-9, trans-11 CLA from the CLA-enriched
butter diet in comparison to the control butter diet.
Studies have demonstrated that cis-9, trans-11 CLA in-
creased the expression of PPARγ, whose down-regulation
may lead to insulin resistance [22]. It was demonstratedFigure 3 Effects of control or naturally enriched in cis-9, trans-11 CLA
Wistar rats fed the following dietary treatments for 60 days: Normal fat-Soybea
Butter (HF-Cb): diet containing 21.7% control butter and 2.3% SO; High Fat-CL
CLA-enriched butter and 2.3% SO; High fat-Soybean oil (HF-So): diet containing
Statistically significant differences were determined by Anova followed by Newmthat CLA mixed with 0.286% cis-9, trans-11 CLA in-
creased the mRNA expression of PPARγ in adipose tissue
of Wistar rats, which was related to improved insulin sen-
sitivity [23]. Besides, it was shown that depletion of PPARγ
in adipose tissue causes insulin resistance, since decreased
PPARγ action in mature adipocytes, leads to reduced ex-
pression of key genes required for insulin signaling in
adipocytes [24]. It was previously shown that adipocyte-
specific constitutive activation of PPARγ in mature adipo-
cytes can regulate whole body insulin sensitivity [25].
Therefore, CLA-enriched butter was shown as having
action mechanisms PPARγ-dependent, up-regulating its
expression in adipose tissue, and preventing PPARγ re-
duction as was observed by a control butter diet.
Rats fed with cis-9, trans-11 CLA-enriched butter had
lower fasting serum insulin levels than rats fed with
control butter. Therefore HF-CLAb diet prevented the
fasting hyperinsulinemia, which is a result potentially
beneficial. According to the European Group for thebutters on serum metabolites. Insulin (A) and glucose (B) of male
n oil (NF-So): diet containing 4.0% soybean oil (SO); High Fat-Control
A enriched Butter (HF-CLAb): diet containing 21.7% cis-9, trans-11
24.0% SO. All data are presented as mean values ± S.E.M (n = 10 rats/group).
an-Keuls. *p <0.05, **p <0.01.
Figure 4 Effects of control or naturally enriched in cis-9, trans-11 CLA butters on lipid serum. Cholesterol (A), triacylglycerol (B), HDL
cholesterol (C) LDL cholesterol (D) of male Wistar rats fed the following dietary treatments for 60 days: Normal fat-Soybean oil (NF-So):
diet containing 4.0% soybean oil (SO); High Fat-Control Butter (HF-Cb): diet containing 21.7% control butter and 2.3% SO; High Fat-CLA
enriched Butter (HF-CLAb): diet containing 21.7% cis-9, trans-11 CLA-enriched butter and 2.3% SO; High fat-Soybean oil (HF-So): diet containing 24.0%
SO. All data are presented as mean values ± S.E.M (n = 10 rats/group). Statistically significant differences were determined by Anova followed by
Newman-Keuls. *p <0.05, **p <0.01, ***p <0.001.
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available simple proxy for insulin resistance, which is de-
fined by presence of fasting hyperinsulinemia [26]. Be-
sides, it was demonstrated that a gradual increase in
serum insulin in the fasting state reflects decreased insu-
lin sensitivity [27]. HOMA index did not differ among
experimental groups, however R-QUICKI index, which
also denotes insulin sensitivity [28], was lower in the
HF-Cb group compared to the NF-So group, while there
was no difference among the NF-So, HF-CLAb and HF-
So groups. Thus, R-QUICKI index shows that control
butter diet induces insulin resistance compared to nor-
mal fat diet, a condition that was not observed in HF-
CLAb group and may be associated to PPARγ reduced
level in adipose tissue of HF-Cb-fed rats [24].
The beneficial effect of cis-9, trans-11 CLA-enriched
butter on fasting insulin level might be due to the higher
supply of cis-9, trans-11 CLA from the CLA-enriched
butter diet in comparison to the control butter diet. It
was previously shown that animals fed with a 0.25% cis-
9, trans-11 CLA diet decreased serum insulin concentra-
tion at fasting [11]. As observed in Table 1, the concen-
trations of several fatty acids were also altered in the
HF-CLAb diet as compared to the HF-Cb diet. For in-
stance, there was a higher (269.72%) supply of vaccenic
acid from HF-CLAb diet compared to HF-Cb diet,which contributed to increase the tissue level of cis-9,
trans-11 CLA in HF-CLAb-fed rats [16]. Furthermore,
there was a lower (32.06%) supply of short and medium-
chain saturated fatty acids from HF-CLAb diet com-
pared to HF-Cb diet, which could also have contributed
to the decreased fasting serum insulin level of the HF-
CLAb group, since it has been suggested that diets high
in saturated fatty acids have effects on hyperinsulinemia
[29-31]. Despite the changed parameters of HF-Cb-fed
rats, the areas under the curves of oral glucose tolerance
tests did not differ among NF-So, HF-Cb, HF-CLAb and
HF-So-fed rats, therefore the experimental diets were
not responsible for glucose intolerance.
Serum NEFA concentration is a risk factor for type 2
diabetes because the combination of excessive levels of
non-esterified fatty acids and glucose leads to decreased
insulin secretion, impairments in insulin gene expression
and beta-cell death by apoptosis [32]. Previous studies
showed that cis-9, trans-11 CLA reduced NEFA levels
[11] however, in the present investigation, there were no
differences among groups. The lack of an effect of butter
enriched in cis-9, trans-11 CLA on NEFA may be attrib-
uted to altered bioavailability and bioactivity of cis-9,
trans-11 CLA when inserted into the fat butter. A simi-
lar hypothesis was developed when it was observed less
distinct effect of high-CLA beef compared to synthetic
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Leptin is an adipokine that plays a role in glucose me-
tabolism and insulin sensitivity [34], however in the
present study there were no differences among groups.
Similarly, it was shown in previous studies that cis-9,
trans-11 CLA did not alter leptin levels [11,22,35].
In the present work, serum cholesterol and LDL
cholesterol concentrations were not modified by the HF-
CLAb diet compared to the NF-So and HF-Cb diets, re-
spectively. Similarly, no effects of cis-9, trans-11 CLA on
cholesterol and LDL cholesterol levels were also shown
previously [36,37]. The high LDL cholesterol concentra-
tion in NF-So-fed rats may be due to high levels of
carbohydrate (73.39% of energy) in this diet, since it was
demonstrated that when dietary carbohydrate was in-
creased from 50% to 67% of energy, the fasting triacyl-
glycerol level rose [38], which is commonly related to
increased precursors of LDL cholesterol in the blood,
the very-low-density lipoproteins, and consequently
increased LDL cholesterol levels [39]. Decreased total
cholesterol concentration in HF-Cb or HF-So-fed
rats was related to the low HDL cholesterol level in
these groups, which is a risk factor for type 2 diabetes
mellitus [40].
Increased triacylglycerol levels in HF-CLAb-fed rats
may be due to higher (160.37%) contents of trans-9 and
trans-10 C18:1 isomers in the HF-CLAb diet compared
to the HF-Cb diet. It has been shown that high intake of
trans-9 C18:1 was correlated to increased plasma con-
centration of triacylglycerol [41] as well as the high
intake of trans-10 C18:1 [42]. Concerning the effect of
cis-9, trans-11 CLA on the triacylglycerol level, previous
studies in animals fed with this CLA isomer did not
modify triacylglycerol concentration [43,44]. However,
rats fed with the HF-CLAb diet had an increased HDL
cholesterol level, which is a potentially beneficial result
because it reduces the risk of having a cardiovascular
event [45] and HDL cholesterol also has a positive effect
on glycemic control [45]. The high level of HDL choles-
terol in HF-CLAb-fed rats may be attributed to a higher
level of cis-9, trans-11 CLA, as also reported by a previ-
ous study [46]. Similarly, it was demonstrated that high
CLA enriched clarified butter increased plasma HDL
cholesterol in Wistar rats [47]. However, it is possible
that the higher supply of oleic acid (cis-9 C18:1)
(27,61%) from the HF-CLAb diet compared to the HF-
Cb diet may also have contributed to increased HDL
cholesterol levels, since it has been suggested that oleic
acid has effects on increasing HDL cholesterol [48]. Be-
sides, there was a lower (36.91%) supply of lauric (C12:0)
and myristic (C14:0) acids from HF-CLAb diet than HF-
Cb diet, which could also have contributed to raised
HDL cholesterol levels of HF-CLAb group, since it was
demonstrated that a lauric and myristic acid-rich dietdecreased HDL cholesterol concentration [49]. On the
other hand, the HF-CLAb diet had higher (147.82%)
levels of trans-9 C18:1, which has been associated with
decreased levels of HDL cholesterol [50]. Therefore, we
hypothesized that fatty acids related to increased HDL
cholesterol level were capable of acting synergistically,
prevailing over negative effects of trans-9 C18:1 isomers
on HDL cholesterol levels, resulting in higher concentra-
tion of this lipoprotein in HF-CLAb-fed rats. However,
concerning the triacylglycerol levels, it has already been
demonstrated by a previous study with animals fed with
butter naturally enriched in cis-9 trans-11 CLA that this
diet had no effect on the plasma concentration of triac-
ylglycerol [14]. Thus, it was possible to hypothesize that
the higher contents of trans-9 and trans-10 C18:1 iso-
mers in the HF-CLAb diet prevailed over the absence of
cis-9 trans-11 CLA effects on triacylglycerol levels,
resulting in a higher concentration of triacylglycerol in
HF-CLAb-fed rats.
Conclusion
In conclusion, the present investigation suggests that a
60 day feeding of a diet containing butter naturally
enriched in cis-9, trans-11 CLA to 60-day-old male
Wistar rats has effects on insulin, HDL cholesterol and tri-
acylglycerol metabolism. Cis-9, trans-11 CLA-enriched
butter significantly raised serum HDL cholesterol and pre-
vented fasting hyperinsulinemia, which could be attributed
to higher levels of cis-9, trans-11 CLA, vaccenic acid, oleic
acid and lower levels of short and medium-chain saturated
fatty acids from CLA-enriched butter compared to control
butter. However, CLA-enriched butter was also found to
cause fasting hypertriglyceridemia, which could be associ-
ated with concomitant increases in the content of trans-9
and trans-10 C18:1 isomers in the CLA-enriched butter.
Additional studies are still needed before conjugated
linoleic acid from natural sources can be used in human
diets as a functional food to decrease type-2 diabetes risk
factors.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Guide for the Care and Use of
Laboratory Animals [51]. All procedures with animals
were approved by the Ethic Committee on Animal Ex-
perimentation of Federal University of Juiz de Fora at
Minas Gerais, Brazil, protocol number 054/2012.
Animals
Forty (n = 40) male Wistar rats (Rattus norvegicus
Berkenhout, 1769), 60 days old and weighing 250–
300 g, were obtained from the Center of Reproduction
Biology of the Federal University of Juiz de Fora,
Table 2 Ingredient composition of experimental diets
Ingredient % of the diet (g/100 g of diet)
Corn starch2 46.6 or 29.1a,b,c,d
Dextronized corn starch2 15.5
Casein1 14.0 or 17.3a,b,c,d
Sucrose1 10.0
Cellulose2 5.0
AIN-93 mineral mix1 3.5
AIN-93 vitamin mix1 1.0
L-Cystine2 0.18
Choline bitartrate2 0.25
tert-Butylhydroquinone1 0.01
SO3 or Butter4 + SOa,b,c 4.0 or 24.0a,b,c,d
1,2Dietary ingredients were purchased from Rhoster (Araçoiaba da Serra, SP,
Brazil) and Farmos (Rio de Janeiro, RJ, Brazil); 3Soybean oil (SO); 4Control Butter
or High CLA Butter. aNormal Fat-Soybean diet consisted of 46.6% corn starch,
14.0% casein and 4.0% SO; bHigh Fat-Control butter diet consisted of 29.1%
corn starch, 17.3% casein and 21.7% Standard Butter + 2.3% SO; cHigh Fat-CLA
enriched butter diet consisted of 29.1% corn starch, 17.3% casein and 21.7%
High CLA Butter + 2.3% SO; dHigh Fat-Soybean oil diet consisted of 29.1% corn
starch, 17.3% casein and 24.0% SO.
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temperature environment (23 ± 2°C) with a photoperiod
of 12 hours (7 a.m. to 7 p.m. - light and 7 p.m. to 7 a.m. -
dark). Water and the experimental diets were offered on
an ad libitum basis to the animals throughout the study.
Production of experimental butters
Experimental butters used in the current study were
produced at Embrapa Dairy Cattle (Juiz de Fora, Minas
Gerais, Brazil). Standard butter and cis-9, trans-11
CLA-enriched butter were produced from milk of cows
(Holstein x Gir) fed diets composed of either corn silage
and concentrate containing no sunflower oil, or chopped
elephant grass and concentrate supplemented with sun-
flower oil at 4.5% of diet dry matter, respectively. The but-
ters were produced as described previously [52].
Dietary treatments and experimental design
After a 7 day acclimatization period in which all animals
were fed a commercial chow (Nuvital, Colombo, PR,
Brazil), the rats were randomly assigned to four dietary
treatments (n = 10/group), for 60 days: 1) Normal fat-
Soybean oil (NF-So): diet containing 4.0% soybean oil
(SO); 2) High Fat-Control Butter (HF-Cb): diet contain-
ing 21.7% control butter and 2.3% SO; 3) High Fat-CLA
enriched Butter (HF-CLAb): diet containing 21.7% cis-9,
trans-11 CLA-enriched butter and 2.3% SO; and 4) High
fat-Soybean oil (HF-So): diet containing 24.0% SO. SO
was included in both HF-Cb and HF-CLAb diets in
order to reach the requirements of linoleic and linolenic
acids to adults rats [53].
All diets were produced according to the American In-
stitute of Nutrition (AIN-93 M) [53]. Ingredients were
carefully mixed in order to obtain a homogeneous mass
which was used to produce handmade pellets. The pel-
lets were prepared weekly, purged with nitrogen and
stored at −20°C in daily portions in sealed polythene
bags to minimize the oxidation of fatty acids. The com-
position of purified diets is presented in Table 2.
Samples of pellets (50 g) from each diet were ran-
domly collected and analyzed for chemical composition
according to reference methods [54,55]. To determine
the fatty acid composition of experimental diets, total
lipids were extracted according to Hara and Radin [56]
using a 3:2 (vol:vol) mixture of hexane and isopropanol
(4.5 mL/g of pellet) followed by a 67 g/L of sodium sul-
fate solution (3 mL/g of pellet). Fatty acid methyl esters
(FAME) were obtained by base-catalyzed transmethylation
using a freshly prepared methylation reagent (0.4 mL of
5.4 mol/L of sodium methoxide solution + 1.75 mL of
methanol) according to Christie et al., [57] with modifica-
tions [58]. The mixture was neutralized with oxalic acid
(1 g of oxalic acid in 30 mL diethyl ether) and calcium
chloride was added to remove methanol residues. TheFAME were determined by gas chromatography (model
6890 N; Agilent Technologies Brasil Ltda., Barueri, Brazil)
fitted with a flame-ionization detector and equipped
with a CP-Sil 88 fused silica capillary column (100 m×
0.25 mm× 0.2 μm film thickness; Varian Inc., Mississauga,
ON). Operating conditions included injector and detector
temperatures both at 250°C, H2 as the carrier gas (1 mL/
min), and for the flame-ionization detector (35 mL/min),
N2 as the makeup gas (30 mL/min), and purified air
(286 mL/min). The initial temperature was 45°C and held
for 4 min, increased by 13°C/min to 175°C and held for
27 min, and increased by 4°C/min to 215°C and held for
35 min [59]. The FAME were identified by comparison
with 4 FAME reference standards (Supelco37 mix #47885-
U, linoleic acid isomers mix #47791, CLA isomers mix
#05632; Sigma-Aldrich, St. Louis, MO, and Nu-Chek
GLC-463); minor trans-18:1 isomers were identified ac-
cording to their elution order reported under the same
chromatographic conditions [59,60]. The fatty acid com-
position of experimental diets was expressed as a weight
percentage of total fatty acids using theoretical relative
response factors described by Wolff et al., [61] (Table 3).
The cis-9, trans-11 CLA content in HF-Cb and HF-
CLAb diets was calculated as follows: (dry matter content
of the diet) x (fat content x 0.95) x (Concentration of cis-9,
trans-11 CLA in g/100 g of total fatty acids). The 5%
discount on fat content was applied to correct for the
glycerol concentration in triacylglycerol molecules [62].
Based on the above-mentioned calculations, the cis-9,
trans-11 CLA contents in HF-Cb and HF-CLAb diets
were 0.075% and 0.235%, respectively. However, consider-
ing that about 11% of vaccenic acid (trans-11 C18:1) is
Table 3 Chemical composition and fatty acid profile of the experimental diets
Dietary treatments
NF-So2 HF-Cb3 HF-CLAb4 HF-So5
Chemical composition,% of diet dry matter
Dry matter content (%) 79.1 86.8 85.4 88.4
Fat 3.11 17.6 17.4 21.1
Crude protein 13.1 16.0 16.2 14.8
Ash 2.76 2.98 3.09 2.95
Neutral Detergent Fiber (NDF) 2.76 3.55 3.26 3.89
Carbohydrate 55.4 44.8 43.4 42.7
Energetic composition
Carbohydrate Energy (%) 73.4 44.6 43.9 40.7
Protein Energy (%) 17.4 15.9 16.4 14.1
Fat Energy (%) 9.35 39.5 39.6 45.2
Kcal/g 2.39 3.49 3.38 3.71
Fatty acids (g/100 g of total fatty acids)
C4:0 n.d.1 3.16 2.95 n.d.
C5:0 n.d. 0.03 0.01 n.d.
C6:0 n.d. 1.69 1.37 n.d.
C7:0 n.d. 0.02 0.01 n.d.
C8:0 n.d. 1.00 0.64 n.d.
C9:0 n.d. 0.03 0.01 n.d.
C10:0 n.d. 2.07 1.14 n.d.
C10:1 cis-9 n.d. 0.26 0.12 n.d.
C11:0 n.d. 0.02 0.01 n.d.
C12:0 n.d. 2.37 1.25 n.d.
C12:1 cis-9/C13:0 n.d. 0.16 0.08 n.d.
C14:0 0.52 8.71 5.74 0.54
C15:0 iso n.d. 0.20 0.25 n.d.
C15:0 anteiso n.d. 0.41 0.47 n.d.
C14:1 cis-9 n.d. 0.83 0.46 n.d.
C15:0 n.d. 0.95 0.90 n.d.
C16:0 11.7 29.3 19.7 11.8
C16:1 trans-9 n.d. 0.03 0.03 n.d.
C17:0 iso n.d. 0.32 0.51 n.d.
C16:1 cis-9 + C17:0 anteiso n.d. 1.51 1.16 n.d.
C17:0 n.d. 0.49 0.51 n.d.
C17:1 cis-9 n.d. 0.18 0.19 n.d.
C18:0 4.25 9.02 13.9 4.23
C18:1 trans-4 n.d. 0.02 0.07 n.d.
C18:1 trans-5 n.d. 0.02 0.06 n.d.
C18:1 trans-6/7/8 n.d. 0.31 0.80 n.d.
C18:1 trans-9 n.d. 0.23 0.57 n.d.
C18:1 trans-10 n.d. 0.30 0.81 n.d.
C18:1 trans-11 n.d. 1.09 4.03 n.d.
C18:1 trans-12 n.d. 0.29 0.65 n.d.
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Table 3 Chemical composition and fatty acid profile of the experimental diets (Continued)
C18:1 trans-13/14 n.d. 0.24 0.49 n.d.
C18:1 cis-9/trans-15 23.8 20.3 25.9 22.4
Minor cis-C18:1 isomers (c11 + c12 + c13) 1.43 0.83 1.03 1.45
C18:1 trans-16 n.d. 0.23 0.36 n.d.
C18:1 cis-14 n.d. 0.05 0.10 n.d.
C19:0/C18:1 cis-15 n.d. 0.11 0.11 n.d.
C18:2 trans-9 trans-12 n.d. 0.01 0.01 n.d.
C18:2 cis-9 trans-12 0.09 0.04 0.06 0.08
C18:2 trans-9 cis-12 n.d. 0.03 0.04 n.d.
C18:2 cis-9 cis-12 49.5 8.04 7.15 52.4
C20:0 0.36 0.18 0.20 0.35
C18:3 cis-6, cis-9 cis-12 n.d. 0.02 0.01 n.d.
C20:1 cis-11 n.d. 0.06 0.12 n.d.
C18:3 cis-9 cis-12 cis-15 6.16 0.96 0.89 6.58
CLA cis-9 trans-11 n.d. 0.53 1.66 n.d.
CLA trans-10 cis-12 n.d. 0.01 0.01 n.d.
CLA trans-11 cis-13 n.d. 0.01 0.02 n.d.
C21:0 n.d. 0.03 0.03 n.d.
C20:2 cis-11, cis-14 n.d. 0.02 0.02 n.d.
C22:0 0.41 0.11 0.13 0.30
C20:3 n-6 n.d. 0.05 0.04 n.d.
C20:4 n-6 n.d. 0.10 0.08 n.d.
C23:0 n.d. 0.03 0.01 n.d.
C20:5 n-3 (EPA) n.d. 0.02 0.01 n.d.
C24:0 0.15 0.06 0.06 0.16
C22:5 n3 (DPA) n.d. 0.06 0.06 n.d.
C22:6 n-3 (DHA) n.d. n.d. n.d. n.d.
1n.d.: not detected; 2Normal Fat-Soybean oil (NF-So), diet containing 4.0% soybean oil (SO); 3High Fat-Control Butter (HF-Cb), diet containing 21.7% control butter
and 2.3% SO; 4High CLA Butter (HF-CLAb), diet containing 21.7% butter naturally enriched in cis-9, trans-11 CLA and 2.3% SO; 5High Fat-Soybean oil (HF-So),
diet containing 24.0% SO.
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the increase expected of cis-9, trans-11 CLA in tissue
levels of HF-CLAb-fed rats is approximately 15% higher
than the levels in HF-Cb-fed rats. The rats were provided
fresh food (Fi) ad libitum daily (between 11 a.m and 12
p.m) and the refusals were weighed the next day (Ff), im-
mediately before the provision of another Fi. Average food
intake (grams/animal) was estimated as follows: (Fi - Ff)/5
(number of animals per cage). Individual body weight was
measured every 5 days throughout the treatment period.
After the treatment period, the rats were fasted for
12 hours (7 a.m. to 7 p.m.) and blood samples collected
from a tail nick for glycemic determinations using the
glucose oxidase method [63]. Immediately after glycemic
determinations, animals were anesthetized with an intra-
peritoneal injection of a xylazine (10 mg/Kg)/ketamine
(90 mg/Kg) solution, and euthanized by total exsanguin-
ation. Glycemic determinations were performed prior toanesthesia as it was shown to induce hyperglycemia [64].
After euthanasia, blood samples, adipose tissue samples
and carcasses were analyzed for parameters related to in-
sulin sensitivity and dyslipidemia in rats.
Analysis of carcass chemical composition
The carcasses were eviscerated, sliced, stored at −80°C,
lyophilized (model Liotop L120; Liobras, São Carlos,
Brazil) and minced in a knife-type mill. Carcasses were
weighed before and after lyophilization to determine
their dry matter contents. Moisture, ash, protein and
lipid contents were determined according to reference
methods [54]. Protein content was quantified using
the Kjeldahl method with Foss equipment (model
Kjeltec 8400, Foss, Hillerød, Denmark) and lipid con-
tent was determined using the Ankom procedure with
an Ankom extractor (model XT10, Ankom Technology,
New York, USA).
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Retroperitoneal adipose tissue samples were homogenized
in a lysis buffer [Tris–HCl: 50 mM, pH 7.4, Na4P2O7:
30 mM, NP-40: 1%, Triton (1%), SDS: 0.1%, NaCl:
150 mM, EDTA: 5 mM, NaF: 50 mM, plus Na3VO4:
1 mM and protease inhibitor cocktail (Roche Diagnostics,
Mannheim, DE)] using an Ultra-Turrax homogenizer
(IKA Werke, Staufen, DE). After centrifugation (7500 × g
for 5 min), the homogenates were stored at −20°C until
SDS-PAGE assay. The total protein content of homogen-
ate was determined by the BCA protein assay kit (Pierce,
Illinois, USA). Contents of peroxisome proliferator-
activated receptor (PPAR)γ and β-tubulin (loading
control) proteins in the retroperitoneal adipose tissue
samples were evaluated by incubating monoclonal primary
antibodies (anti-PPARγ and anti-β-tubulin; 1:1000; from
Abcam, Cambridge, UK) overnight at 4°C, followed by
proper secondary antibody (1 hour; 1:7000 antibody
from Sigma-Aldrich Co., Missouri, USA) and strepta-
vidin (1 hour; 1:7000; Zymed, California, USA) incubation.
The protein bands were visualized by chemiluminescence
with Kit ECL Plus (GE Healthcare Life Sciences,
Buckinghamshire, UK) followed by exposure in the
ImageQuant™ LAS 500 (GE Healthcare Life Sciences).
Area and density of the bands were quantified by
Image J software (Media Cybernetics, Maryland, USA).
The results were normalized by β-tubulin content and
expressed as relative (%) to NF-So group.
Serum metabolites
Blood samples were collected from euthanized animals
by cardiac puncture and centrifuged (5714 × g for 5 min)
for serum separation. Serum insulin levels were deter-
mined using a rat insulin ELISA kit (Mercodia, Uppsala,
Sweden). Serum non-esterified fatty acids (NEFA) levels
were analyzed using a colorimetric kit (Randox La-
boratories, Antrim, United Kingdom), while leptin was
analyzed using a Leptin ELISA kit (R&D Systems,
Minneapolis, USA). Serum levels of cholesterol, triac-
ylglycerol, HDL cholesterol and LDL cholesterol were
determined by colorimetry using the BT 3000 equip-
ment from Wiener laboratories.
HOMA and R-QUICKI
Homeostatic Model Assessment (HOMA) index was
calculated as follows: [fasting insulin (ng/ml) × fasting
glucose (mM)]/22.5. A high HOMA index denotes low
insulin sensitivity [65], although it should be acknowl-
edged that the HOMA model has not been validated for
use in animal models [66]. The Revised Quantitative In-
sulin Sensitivity Check Index (R-QUICKI) is another
equation to assess insulin sensitivity [28]. This index was
calculated as following: [1/log fasting insulin (mU/ml) +
log fasting glucose (mg/dl) + log NEFA (mmol/l)] [28].Oral glucose tolerance test (OGTT)
After 55 days on the experimental diets, the rats were
fasted for 12 hours (7 a.m. to 7 p.m) and received a 50%
glucose solution (2 g/kg body weight) by oral gavage
[67]. Blood samples were collected from a tail nick for
glycemic determinations using the glucose oxidase
method [63] at 0, 30, 60, 90, 120 and 240 minutes post
gavage. Due to reasons previously described, anesthesia
was not used in the OGTT. Changes in blood glucose
concentration during the oral glucose tolerance test were
evaluated by estimation of the total area under the curve
(AUC) calculated as an incremental considering the re-
sponse from the starting point that was analyzed and
using the trapezoidal method [68].
Statistical analysis
The statistical analyses were performed using Prism 5.0
(GraphPad Software, Inc). Data from different dietary
groups were analyzed by one-way ANOVA for overall
significance followed by Newman-Keuls’s post-hoc tests
to identify differences between treatment groups. Results
were expressed as means ± SEM (standard error mean).
Treatment effects and differences between means were
considered significant when p < 0.05.
Additional files
Additional file 1: Complete electrophoretic blot of representative
bands of PPARγ level in adipose tissue of Wistar rats. Figure containing
complete electrophoretic blot of representative bands of PPARγ level
shown in Figure 2.
Additional file 2: Complete electrophoretic blot of representative
bands of PPARγ level in adipose tissue of Wistar rats. Figure
containing complete electrophoretic blot of representative bands of
PPARγ level shown in Figure 2. In this file we indicate the experimental
group related to each band.
Additional file 3: Complete electrophoretic blot of representative
bands of β-tubulin (loading control) level in adipose tissue of Wistar
rats. Figure containing complete electrophoretic blot of representative
bands of β-tubulin level shown in Figure 2.
Additional file 4: Complete electrophoretic blot of representative
bands of β-tubulin level (loading control) in adipose tissue of Wistar
rats. Figure containing complete electrophoretic blot of representative
bands of β-tubulin level shown in Figure 2. In this file we indicate the
experimental group related to each band.
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